NasdaqCM - Nasdaq Real Time Price USD

MIRA Pharmaceuticals, Inc. (MIRA)

0.9942

+0.0732

+(7.95%)

At close: April 24 at 4:00:01 PM EDT

0.9700

-0.02

(-2.43%)

After hours: April 24 at 7:42:15 PM EDT

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced ...

ACCESS Newswire yesterday

MIRA
+7.95%
MIRA Pain Treatment Expands Market Size Potential

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The

Zacks Small Cap Research yesterday

MIRA
+7.95%
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical ...

ACCESS Newswire 8 days ago

MIRA
+7.95%
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy, a type of nerve damage that can occur in diabetes patients. In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin (STZ). Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre

Benzinga 8 days ago

MIRA
+7.95%
MIRA Continues Positive Testing Run

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The

Zacks Small Cap Research 8 days ago

MIRA
+7.95%
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment ...

ACCESS Newswire 23 days ago

MIRA
+7.95%
MIRA Enrolls Patients Amid Rapid Progress

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The

Zacks Small Cap Research 23 days ago

MIRA
+7.95%
Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

Stock index futures are experiencing a notable surge, reflecting renewed investor optimism, primarily driven by reports suggesting that the U.S. administration may reduce the scope of proposed tariffs, potentially excluding certain sectors. Such developments have bolstered market sentiment, leading to premarket gains across major indices. In the commodities market, oil prices have experienced a slight decline as investors closely monitor ongoing ceasefire talks between Russia and Ukraine. The

TipRanks 30 days ago

ALC

PENG

OKLO
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking. MIAMI, FL / ACCESS Newswire / March 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ...

ACCESS Newswire last month

MIRA
+7.95%
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug

On Monday, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The transaction includes a $5 million capital infusion of cash or equivalent consideration into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation. Also Read: EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

Benzinga last month

MIRA
+7.95%
MIRA Makes Significant Acquisition and Boosts Capital

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The

Zacks Small Cap Research last month

MIRA
+7.95%
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement. ATAI DOSES FIRST PATIENT IN PHASE 2 VLS-01 TRIAL: atai Life Sciences (ATAI) announced Tuesday that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine applied to the buccal surface, in people suffering from tre

TipRanks last month

ATAI

MNMD

CMND
MIRA Makes Another Pain Management Stride

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The

Zacks Small Cap Research last month

MIRA
+7.95%
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful formulation ...

ACCESS Newswire last month

MIRA
+7.95%
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and upcoming ...

ACCESS Newswire last month

MIRA
+7.95%
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

On Tuesday, the Israeli Ministry of Health and the Institutional Review Board (IRB) approved MIRA Pharmaceuticals, Inc.'s (NASDAQ:MIRA) Phase 1 trial for Ketamir-2, the company's novel oral ketamine analog in development for neuropathic pain. In December, MIRA Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA to start human trials for Ketamir-2. MIRA's preclinical studies demonstrate Ketamir-2's superior efficacy, safety, and optimized pharmacokinetics, supportin

Benzinga last month

MIRA
+7.95%
MIRA Announces Approval of Important Testing

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The

Zacks Small Cap Research last month

MIRA
+7.95%
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 3 months ago

MIRA
+7.95%
Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea

A profit opportunity led to nearly $100 million in trading volumes for a charity-themed memecoin. While some speculators lost money, the effort bore fruit for the original cause.

CoinDesk 3 months ago

MIRA
+7.95%
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) application ...

ACCESS Newswire 4 months ago

MIRA
+7.95%

Performance Overview

Return	MIRA	S&P 500 (^GSPC)
YTD	-12.79%	-6.75%
1-Year	+14.28%	+8.15%
3-Year	-85.05%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pain Treatment Expands Market Size Potential

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

MIRA Continues Positive Testing Run

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Enrolls Patients Amid Rapid Progress

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug

MIRA Makes Significant Acquisition and Boosts Capital

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

MIRA Makes Another Pain Management Stride

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

MIRA Announces Approval of Important Testing

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Performance Overview